Tyler Jacks

Tyler Jacks

Director, Koch Institute for Integrative Cancer Research; David H. Koch Professor of Biology; Daniel K. Ludwig Scholar for Cancer Research; Investigator, Howard Hughes Medical Institute

Tyler Jacks is interested in the genetic events contributing to the development of cancer, and his group has created a series of mouse strains engineered to carry mutations in genes known to be involved in human cancers.

617-253-0262

Phone

76-453

Office

Judy Teixeira

Assistant

617-253-0263

Assistant Phone

Education

  • PhD, 1988, University of California, San Francisco
  • SB, 1983, Biology, Harvard University

Research Summary

Dr. Jacks’ research has focused on developing new methods for the construction and characterization of genetically engineered mouse models or GEMMs of human cancer, and recently has moved into the burgeoning area of tumor immunology to understand the interactions between the immune system and cancer.  His group has produced GEMMs with constitutive and conditional mutations in several tumor suppressor genes, oncogenes, and genes involved in oxidative stress, DNA repair and epigenetic control of gene expression. These GEMMS have been used to examine the mechanism of tumor initiation and progression, to uncover the molecular, genetic and biochemical relationship to the human diseases, as tools to study response and resistance to chemotherapy, and to explore methods in molecular imaging and early detection of cancer.

Awards

  • Massachusetts Institute of Technology, James R Killian Jr Faculty Achievement Award, 2015
  • Sergio Lombroso Award in Cancer Research, 2015
  • American Academy of Arts and Sciences, Fellow, 2012
  • National Academy of Sciences, Member, 2009
  • Institute of Medicine of the National Academies, Member, 2009
  • Paul Marks Prize for Cancer Research, 2005
  • Howard Hughes Medical Institute, HHMI Investigator, 1994

Key Publications

  1. Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Joshi, NS, Akama-Garren, EH, Lu, Y, Lee, DY, Chang, GP, Li, A, DuPage, M, Tammela, T, Kerper, NR, Farago, AF et al.. 2015. Immunity 43, 579-90.
    doi: 10.1016/j.immuni.2015.08.006PMID:26341400
  2. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Xue, W, Chen, S, Yin, H, Tammela, T, Papagiannakopoulos, T, Joshi, NS, Cai, W, Yang, G, Bronson, R, Crowley, DG et al.. 2014. Nature 514, 380-4.
    doi: 10.1038/nature13589PMID:25119044
  3. Expression of tumour-specific antigens underlies cancer immunoediting. DuPage, M, Mazumdar, C, Schmidt, LM, Cheung, AF, Jacks, T. 2012. Nature 482, 405-9.
    doi: 10.1038/nature10803PMID:22318517
  4. The differential effects of mutant p53 alleles on advanced murine lung cancer. Jackson, EL, Olive, KP, Tuveson, DA, Bronson, R, Crowley, D, Brown, M, Jacks, T. 2005. Cancer Res 65, 10280-8.
    doi: 10.1158/0008-5472.CAN-05-2193PMID:16288016
  5. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Johnson, L, Mercer, K, Greenbaum, D, Bronson, RT, Crowley, D, Tuveson, DA, Jacks, T. 2001. Nature 410, 1111-6.
    doi: 10.1038/35074129PMID:11323676

Recent Publications

  1. Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma. LaFave, LM, Kartha, VK, Ma, S, Meli, K, Del Priore, I, Lareau, C, Naranjo, S, Westcott, PMK, Duarte, FM, Sankar, V et al.. 2020. Cancer Cell 38, 212-228.e13.
    doi: 10.1016/j.ccell.2020.06.006PMID:32707078
  2. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Ng, SR, Rideout, WM 3rd, Akama-Garren, EH, Bhutkar, A, Mercer, KL, Schenkel, JM, Bronson, RT, Jacks, T. 2020. Proc Natl Acad Sci U S A 117, 513-521.
    doi: 10.1073/pnas.1821893117PMID:31871154
  3. IL-33 Signaling Alters Regulatory T Cell Diversity in Support of Tumor Development. Li, A, Herbst, RH, Canner, D, Schenkel, JM, Smith, OC, Kim, JY, Hillman, M, Bhutkar, A, Cuoco, MS, Rappazzo, CG et al.. 2019. Cell Rep 29, 2998-3008.e8.
    doi: 10.1016/j.celrep.2019.10.120PMID:31801068
  4. Identification of DHODH as a therapeutic target in small cell lung cancer. Li, L, Ng, SR, Colón, CI, Drapkin, BJ, Hsu, PP, Li, Z, Nabel, CS, Lewis, CA, Romero, R, Mercer, KL et al.. 2019. Sci Transl Med 11, .
    doi: 10.1126/scitranslmed.aaw7852PMID:31694929
  5. Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Schmidt, L, Eskiocak, B, Kohn, R, Dang, C, Joshi, NS, DuPage, M, Lee, DY, Jacks, T. 2019. Proc Natl Acad Sci U S A 116, 17460-17469.
    doi: 10.1073/pnas.1904253116PMID:31409707
  6. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Jin, C, Lagoudas, GK, Zhao, C, Bullman, S, Bhutkar, A, Hu, B, Ameh, S, Sandel, D, Liang, XS, Mazzilli, S et al.. 2019. Cell 176, 998-1013.e16.
    doi: 10.1016/j.cell.2018.12.040PMID:30712876
  7. Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Dayton, TL, Gocheva, V, Miller, KM, Bhutkar, A, Lewis, CA, Bronson, RT, Vander Heiden, MG, Jacks, T. 2018. Cancer Metab 6, 6.
    doi: 10.1186/s40170-018-0179-2PMID:29854399
  8. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. Chen, PY, Muzumdar, MD, Dorans, KJ, Robbins, R, Bhutkar, A, Del Rosario, A, Mertins, P, Qiao, J, Schafer, AC, Gertler, F et al.. 2018. Cancer Res 78, 985-1002.
    doi: 10.1158/0008-5472.CAN-17-2129PMID:29279356
  9. Survival of pancreatic cancer cells lacking KRAS function. Muzumdar, MD, Chen, PY, Dorans, KJ, Chung, KM, Bhutkar, A, Hong, E, Noll, EM, Sprick, MR, Trumpp, A, Jacks, T et al.. 2017. Nat Commun 8, 1090.
    doi: 10.1038/s41467-017-00942-5PMID:29061961
  10. Driving Rel-iant Tregs toward an Identity Crisis. Li, A, Jacks, T. 2017. Immunity 47, 391-393.
    doi: 10.1016/j.immuni.2017.08.014PMID:28930651
More Publications

Multimedia

 

 

Photo credit: Alisha Siegel